Introduction
Ovarian cancer is the fourth most common cancer death in women. Early stages of the disease are often asymptomatic and, at the time of diagnosis, the majority of women have advanced disease. Control of the disease has improved over the last twenty years with the use of aggressive cytoreduction, platinum-based chemotherapy and more recently taxanes [1, 2] . However, the majority of patients still relapse and die of their disease; only 25%-30% of patients with advanced (FIGO stage III or IV) disease remain alive at five years [3, 4] .
Dose-intensification of chemotherapy may overcome a relative resistance in the tumour to cytotoxic drugs. This approach has been shown to be beneficial in the treatment of lymphomas and intensive chemotherapy is being explored in common solid tumours. Ovarian cancer is very chemosensitive; typically more than 70% of patients will respond to chemotherapy. A retrospective analysis has shown that tumour response and survival are related to drug dose-intensity [5, 6] . Prospective randomized studies have generally not supported this view [7] . However, the level of dose escalation has been small; patients usually received about twice the standard dose of drug.
Very high doses of chemotherapy require the support of autologous marrow, or peripheral blood stem cells and granulocyte colony-stimulating factors. Early reports of high-dose chemotherapy in ovarian cancer were mainly confined to small numbers of patients with disease that is usually resistant to standard chemotherapy [8] . More recently a few centres have reported their results in larger cohorts of patients [9] [10] [11] [12] [13] .
The Solid Tumour Registry for the EBMT was set up in 1981 and the Solid Tumour Working Party established in 1984 now has data on over 14,000 patients treated with high dose chemotherapy. We report the experience of high-dose therapy in 256 patients with ovarian carci- 
Patients and methods
Between October 1982 and January 1996, a total of 256 patients with a diagnosis of ovarian cancer from 39 centres in Europe were registered with the EBMT The registration details of these patients were reviewed. Ovarian cancer was diagnosed between September 1975 and December 1995. The reporting physicians were contacted and asked to provide additional details where these had been omitted. Further information was requested on primary tumour site, initial treatment, high dose chemotherapy drugs, and follow-up As this is a report of registry data there are cases where information is incomplete. This is indicated in the tables above.
Patient characteristics
Patient characteristics at diagnosis are listed in Table 1 . For the 256 patients, median age was 46 years (range 14-63 years). One patient with a Krukenberg tumour and one patient with a granulosa cell tumour have been removed from the analysis Details of the centres entering patients are given in the Appendix. The youngest, aged 14 years had a FIGO stage IIIC papillary-serous carcinoma. More than 90% of patients had FIGO stage III or IVdisease: stage was unknown in 2.4% of cases. The histological subtype was given in more than half the patients. In 28% it was given as unspecified epithelial ovarian cancer and in 18 1% data were missing.
Initial therapy
Surgery was performed in 64.1% of patients. In 64 patients (25 2%) there was either microscopic or no residual disease following surgery. Macroscopic disease was known to be present in 42.5% of patients after diagnosis because of incomplete debulking surgery at laparotomy or because only biopsies were taken. Furthermore it was recorded that no surgery was performed in 10.6%, and in 21 7% there were no details of the diagnostic procedure These figures arc summarised in Table 2 which also contains details of the initial treatment. Chemotherapy was given to most patients and three quarters of the group received platinum-based therapy. . Radiotherapy was used in a high proportion of patients. All of these patients were from centres in France and nearly all were treated between 1990 and 1993. Forty-two patients were in the CR1 group. All the others were given radiotherapy as part of a relapse regimen The practice in some of the French centres was to give 25 Gy whole abdominal radiation in patients who attained CR, or after a 'second-look' procedure. Details of the dose and timing of radiotherapy in these patients is not complete.
Statistical analysis
The overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan-Meier method. Differences between groups were assessed by the log-rank test using the SAS software OS and DFS were calculated from date of autologous bone marrow or stem-cell re-infusion, or the date of diagnosis to the date of death from any cause for OS or to the date of the first event for DFS
Results

Patient characteristics at time of graft and high-dose therapv
The disease status before high-dose therapy is summarised in Table 3 . Data from 288 grafts were analysed. Eighteen patients received double grafts and eight patients received triple grafts. One hundred five patients (41.3%) received high-dose therapy in first remission (CR1) or very good partial first remission (VGPR1), defined as microscopic residual disease at a 'secondlook' procedure. Within this group 3 patients had early stage (I or II) disease, 76 stage III, 24 stage IV and in 2 patients the stage was unknown. It is not clear why three patients with early stage disease proceeded to high-dose therapy. One patient with stage I disease was defined as having VGPR1 and underwent high-dose treatment nine months after diagnosis. The other 2 patients both received high-dose chemotherapy 12 months after diagnosis at which time they were classified as being in CR1. Twentynine out of sixty-four patients with microscopic or no residual disease after initial surgery were in the CR1 or VGPR1 group. We do not know how many of the remaining 76 patients in CR1 or VGPR1 had little disease at the end of their operation as surgical details were not recorded in 55 patients. Thirteen out of sixteen patients with stage I or II disease received high-dose chemotherapy after relapse; five were in a second complete remission and the rest had residual macroscopic disease which was classified by the investigators as either 'resistant' or 'sensitive' to chemotherapy. A further 22 patients were in second complete remission at the time of high-dose chemotherapy and 116 (45.6%) patients were not in a remission when they received high-dose chemotherapy. In six patients the disease status at the time of high dose chemotherapy was unknown. Details of the second line chemotherapy were not well recorded; 79 patients were known to have had 'second-line'chemotherapy.
Graft and high-dose therapy regimens
Over time there has been a gradual change from autologous bone marrow transplantation (ABMT) to peripheral blood stem-cell transplantation (PBSCT). ABMT was performed in 155 patients, 8 patients received ABMT and PBSCT, and 120 received PBSCT (data were unavailable for 5 grafts) (Figure 1 ). The high-dose therapy regimens used for the 288 grafts are listed in Table 4 . Overall, 85.8% of regimens included platinum-based drugs, chiefly carboplatin and/or melphalan. The 23 regimens containing agents other than cisplatin or carboplatin and melphalan all contained cyclophosphamide.
Most patients in first complete or partial remission received their transplant within 12 months of diagnosis. The time to transplantation was much more variable, as expected in patients transplanted in second CR. All received high-dose therapy more than 12 months after diagnosis and the majority were transplanted between 2 and 3 years after diagnosis. Overall 174 (68.5%) of patients received high-dose chemotherapy within 12 months of diagnosis.
Outcome
The data were frozen on 1 October 1998 to perform the analysis. The overall survival and duration of remission (disease-free survival following transplantation) was significantly longer in patients given high-dose chemotherapy in remission (CR1, second CR or VGPR1) than in those receiving high-dose chemotherapy in a partial remission, or with stable or resistant disease. The median survival of 132 patients transplanted in remission was 33 months from the graft compared with 14 months in those who were not (P = 0.0001). The median followup is greater than five years and no patient in the CR group has relapsed beyond three and a half years (Figures 2a and b) . Patients who received high-dose therapy in first remission or VGPR1 had a more durable remission than those transplanted in second CR. The median disease-free survival was 18 months versus 9 months {P = 0.005) (Figure 3) . Although the diseasefree survival was significantly lengthened there was no significant difference in the overall survival following the graft (P = 0.15) (data not shown). Table 5 shows the outcome in different groups and the timing of the high dose regimen. Most patients in CR1, VGPR or PR were transplanted 6-12 months after diagnosis. Comparisons of survival with groups transplanted outside these times are difficult as the size of the groups is small. Figure 4 shows the survival of the 76 stage III and 24 stage IV patients transplanted in first remission. The median follow-up was 76 months from diagnosis. The median disease-free survival is 42 months for stage III and 26 months for stage IV patients (Figure 4a ) and the median overall survival is 59 months for stage III and 40 months for stage IV patients (Figure 4b ). The differences are not statistically significant.
Toxicity
One hundred sixty-nine patients relapsed or progressed after the last transplant (no information is available on six patients). One hundred fifty-seven patients died and the cause of death was available for one hundred twentyfour patients. The cause of death was original disease alone in 97 patients and other causes including original disease in a further 8 patients. Procedure-related deaths within 90 days occurred in 18 patients (7%), principally infection, haematological toxicity and multi-organ failure. Original disease contributed to the cause of death in 3 patients who died within 90 days. 
Discussion
The large number of patients reported to the solid tumour registry of the EBMT over the last decade reflects the growing interest in high dose chemotherapy. Ovarian cancer is a disease with a high response rate to chemotherapy but a poor long-term survival [4] , Although there have been several previous publications of high dose chemotherapy in ovarian cancer only a few have information on >20 patients [9-11, 13-15]. Stiff et
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al. [15] have had the largest single centre experience of treating patients with relapsed disease and their conclusions that high-dose chemotherapy should not be given to patients other than those in remission or who have 'drug-sensitive' disease is supported by our findings. The overall survival of patients who are not in remission at the time of high-dose chemotherapy is poor. A median survival of 14 months post high-dose chemotherapy shows that many patients died soon after therapy. Less than 20% survived more that five years after the procedure; these are probably the few patients with 'drug-sensitive' disease who were given high-dose therapy. There are, however, a group of patients given high-dose therapy to consolidate remissions that fare significantly better. This group, comprising just over half the total patients in our series had a five-year survival after transplantation of just under 40%. Their median survival of 33 months following consolidation therapy suggests that high-dose treatment may favourably affect the natural history of advanced ovarian cancer. Furthermore, half the patients have been followed for more than five years and late relapse is uncommon (Figure 2b ). This group of patients consists largely of patients given consolidation high-dose therapy in CRI or VGPR1. A smaller number of patients were treated in second remission. The stability of the response to treatment, shown in Figure 3 indicates that patients transplanted in first remission have a significantly better outcome. Interestingly, the overall survival of the two groups is not different, probably reflecting the presence of continuing 'drug-sensitivity' in a proportion of patients who attain a second remission. Legros et al. [13] from ClermontFerrand, France, has the greatest published experience of high-dose chemotherapy in first-line therapy of patients with advanced ovarian cancer. For patients with no macroscopic disease at the end of initial chemotherapy the survival of patients, some of whom are included in the EBMT data set was 71.2% at five years. In the EBMT registry the median survival from diagnosis of patients in CRI or VGPR1 was 54 (4.5 years) months. The median disease-free survival of the Clermont-Ferrand group was 36.7 months for 31 patients in clinical remission, virtually identical to our finding of 32 months in 105 patients.
An analysis of long-term outcome of patients treated with standard doses of platinum-based chemotherapy has been reported by Neijt et al. [3] for the Netherlands Joint Study Group. The longest survival was seen in patients with a surgically defined complete response. In this group the median survival was 7.8 years falling to 4.2 years in patients who had residual microscopic disease after platinum-based chemotherapy. The five-year survival of these two groups were 64% and 35%. The majority of patients in our series did not have a surgically defined response. At least 17 patients had microscopic disease. We know that only 29 patients out of 105 had no macroscopic disease at the end of primary surgery. Even if all the 55 patients in the unknown disease category at the start of treatment were added to this group there would still be at least 20% of patients who started treatment with macroscopic disease. The group in clinical remission (CRI) is a heterogeneous group, some of whom had a pathological complete remission and others with microscopic or larger disease, not clinically detectable.
One hundred out of one hundred five patients transplanted in CRI or VGPR1 had stage III or IV disease. The median survival of these two groups was 59 and 40 months, respectively, which was not significantly different. At five years the probability of survival is 48% for patients with stage III disease and 35"% of patients with stage IV ovarian cancer. The median follow-up is in excess of five years and it appears from the disease-free survival curve in Figure 4b that late relapse is an uncommon event. The mature survival data from trials in ovarian cancer demonstrate how large differences in outcome become apparent with time depending on prognostic factors, particularly the response to first-line chemotherapy [3, 16] . Patients in CRI or VGPRl represent a more favourable group of patients with stage III or IV disease but as data on prognostic variables are incomplete it is difficult to quantify the magnitude of this effect. For example, data on tumour sub-type and grade was lacking in many cases. Furthermore, 40% of patients in the CRI/VGPR group received abdominal radiotherapy as part of their first-line therapy. Although it is generally believed that the addition of radiotherapy does not contribute to the effect of chemotherapy in ovarian cancer one cannot exclude this as a possible factor to account for the survival results. Firm conclusions cannot be drawn but the hypothesis generated from these data is that high-dose consolidation therapy may have benefited patients with less favourable prognostic features such that the overall outcome of the subset of patients in CRI and VGPR is as good as those of patients with a surgically documented remission. There has recently been criticism of the dose-intense approach [7, 17] although much of this has been directed at studies where there have been only a two-fold increase in the dose delivered. Very high doses of chemotherapy can be given if bone marrow toxicity is the dominant side-effect. Melphalan and carboplatin are most commonly used and the dose of both drugs can be escalated significantly and may be given sequentially [18] [19] [20] . The majority of patients were given high dose carboplatin or melphalan and 24% received a combination of the two. The toxicity of high dose chemotherapy is a concern to many. The overall procedure-related (90-day) mortality was 7%. This is higher than one would now accept in a unit that has experience in high-dose chemotherapy. As shown in Figure 1 , PBSCT, which started in 1992, is now replacing ABMT which was used for most patients in this study. The faster haematological recovery following PBSCT, use of granulocyte colony stimulating growth factors and increasing familiarity with the care of patients undergoing this type of therapy has led to a fall in the procedure-related mortality which has not been greater than 3% since 1993 (EBMT Solid Tumour Registry and Working Party Report 1999).
The EBMT series and American Bone Marrow Transplant Registry contain between them information on more than 650 patients [21, 22] . The series from the USA contains mainly patients transplanted after extensive previous chemotherapy. In this report from the EBMT two-thirds of patients were transplanted after first-line therapy and 41% received high-dose therapy as consolidation of first remission. Although the EBMT registry contains an heterogeneous group of patients the size of the data set allows subgroups of patients to be studied. There are two main conclusions. The first, shared by Stiff et al. [22] is that there can be no role for consolidation high-dose therapy in patients who are not in remission after chemotherapy, or who have bulky disease after chemotherapy. Secondly, the results of treatment of patients in remission appears better than after current standard therapy. However, a note of caution should be sounded as the registry data set do not constitute either a cohort or randomly assigned group. There is now an urgent need to conduct prospective randomised studies in the first-line treatment of ovarian cancer.
Three randomized trials of consolidation chemotherapy were started a few years ago. A French GIN ECO (Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire) study expects to close this year with 120 patients. A second study from Finland (FINOVA) continues to recruit slowly and a third from the Gynecologic Oncology group closed early as it was difficult to recruit patients to a consolidation arm that contained either high-dose or more standard therapy. The EBMT have adopted a different approach using sequential highdose chemotherapy. Patients are randomized after surgery to receive either standard platinum-paclitaxel therapy or two cycles of cyclophosphamide and paclitaxel followed by three cycles of paclitaxel with peripheral blood stem cell supported high-dose carboplatin and high-dose melphalan added to the final cycle. A pilot study showed this to have acceptable toxicity [23] . This trial, OVCAT has recently been launched and is very similar to a study being conducted by a German group. High-dose chemotherapy is costly and there is scepticism about its use. The data presented from this study provide encouragement to proceed with randomised studies [24] . Only then will we know whether high dose chemotherapy is useful or if it should be laid to rest. *Appendix
